DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN Portugal ONLY.

Information about the NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) (also known as NVX-CoV2373)

NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) has been granted a conditional marketing authorisation for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older, and as a booster dose approximately 6 months after the second dose in individuals 18 years of age and older.

Report an Adverse Event (AE)

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of Portugal.

Sítio da internet: www.infarmed.pt/web/infarmed/submissaoram
(preferencialmente)
ou através dos seguintes contactos:
Direção de Gestão do Risco de Medicamentos
Parque da Saúde de Lisboa, Av. Brasil 53
1749-004 Lisboa

Tel: +351 21 798 73 73
Linha do Medicamento: 800222444 (gratuita)
e-mail: [email protected]

Contact Us

Tel: +351 21 020 6287
09:00 - 17:00
Monday - Friday